Table 2.

Patient infection/reactivation status and outcome

PatientIndicationPrior therapyViral course after VSTStatus within first year
P0123Adenovirus low-level viremia (<200 copies per mL) and positive upper respiratory tractCidofovirResolution (with brincidofovir)Alive, GVHD resolved at 1 y
P0067CMV 2239 cells per mLFoscarnet/cidofovir/ganciclovirCMV viremia resolved by 6 mo but developed CMV retinitis 6 mo after infusionAlive, CMV retinitis at 6 mo treated with third-party T cells and intravitreal ganciclovir with complete resolution, GVHD resolved at 1 y
P0039CMV low-level viremia (<1000 copies per mL)Foscarnet/cidofovir/ganciclovirResolutionLeukemia relapse after 90 d, in remission after CAR T-cell therapy
P0035CMV low-level viremia (<1000 copies/mL) and positive stoolFoscarnetResolution (with valganciclovir)Alive, quiescent GVHD on cyclosporine at 1 y
P2891CMV viremia (100 copies/mL)Foscarnet, CMV immunoglobulinResolution (with ganciclovir + 2 additional CB-VST infusions)Alive, GVHD resolved at 1 y
P3626EBV in bone marrow (3500 copies/mL)Cidofovir for previous adenoviremiaFivefold decline in bone marrow EBV at 5 mo, negative in blood at 1 y, no PTLDAlive, MDS + monosomy 7 at <1 y resolved at 2 y. No GVHD, off immunosuppression at 1 y
P3457EBV viremia (109 copies/mL)NonePersistent viremia but no PTLDDied after second transplant for relapsed leukemia
P3010ProphylaxisGanciclovir prophylaxisNo reactivation requiring therapy, no diseaseAlive, no GVHD, off immunosuppression at 1 y
P3275ProphylaxisNoneNo reactivation requiring therapy, no diseaseAlive, no GVHD, off immunosuppression at 1 y
P3317ProphylaxisGanciclovir prophylaxisNo reactivation requiring therapy, no diseaseRelapse/AML progression <1 y after HCT, deceased day +284.
P3531ProphylaxisValganciclovir prophylaxisNo reactivation requiring therapy, no diseaseAlive, no GVHD, off immunosuppression at 1 y
P3555ProphylaxisNoneNo reactivation requiring therapy, no diseaseAlive, resolved GVHD at 1 y
P3923ProphylaxisNoneNo reactivation requiring therapy, no diseaseAlive, no GVHD, off immunosuppression at 1 y
P0020Prophylaxis/past history of adenovirus in stoolCidofovirAdenovirus reactivation in stool at 3 wk and then blood 3 mo after VSTs; given second CB-VST infusion and continued with cidofovirAlive, quiescent GVHD on cyclosporine at 1 y
  • CAR, chimeric antigen receptor; HCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; PTLD, posttransplantation lymphoproliferative disorder.